Breakthrough EU approval for Dupixent offers new hope for children with eosinophilic esophagitis

Pallavi Madhiraju- November 8, 2024 0

The European Medicines Agency (EMA) has granted approval for Dupixent, a therapy developed by Sanofi and Regeneron, to treat eosinophilic esophagitis (EoE) in children as ... Read More

EMA approves Dupixent as first biologic for COPD with elevated eosinophils

Pallavi Madhiraju- July 7, 2024 0

The European Medicines Agency (EMA) has granted approval to Dupixent (dupilumab) as a novel add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease ... Read More

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

Raghuram Kadari- February 1, 2023 0

French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More

Dupixent delivers positive results in eosinophilic esophagitis trial

pharmanewsdaily- May 24, 2020 0

Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More

Dupixent receives FDA approval for treatment of moderate-to-severe asthma

pharmanewsdaily- October 21, 2018 0

Sanofi and Regeneron Pharmaceuticals' Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance ... Read More

Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment

pharmanewsdaily- April 2, 2017 0

Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More

Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial

pharmanewsdaily- March 5, 2017 0

Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More